ERBB2 and neoplasm: It consists of a humanized IgG1 anti-HER2 monoclonal antibody conjugated with a potent topoisomerase I inhibitor DXd via tetrapeptide-based cleavable linker, which enables the targeted delivery of the cytotoxic agent to tumor cells expressing HER2.